Co-Founder & Chief Executive Officer, Epitracker
Stephanie Venn-Watson is a veterinary and entrepreneurial leader with 18 years' experience founding and growing public health and life science programs. Stephanie has been dedicated to improving marine mammal and human health, including founding the Translational Medicine and Research Program at the National Marine Mammal Foundation and co-founding Epitracker. Stephanie’s innovative discoveries have been featured on NPR’s Science Friday, CBS, BBC, and National Geographic. Her "One Health" approach to discovering novel treatments for dolphins and humans have been invited talks for Biocom’s Annual Dinner (2014), J&J Innovations: Powerful Ideas Series (2015), San Diego Venture Group's Hot Topic Series (Venture Summit 2015), LA BioMed Innovation Showcase (2016), and San Diego's Innovation Showcase (2017). She has over 60 peer-reviewed scientific publications. Stephanie received her B.S. in Animal Physiology and Neuroscience from UC San Diego, D.V.M. from Tufts University, M.P.H. from Emory University, and was a National Research Council Associate with the Armed Forces Medical Intelligence Center. Stephanie has worked for the Centers for Disease Control and Prevention, World Health Organization, and Defense Advanced Research Projects Agency. She is an Albert Schweitzer Fellow for Life and received the Department of Health and Human Services Secretary’s Award for Innovations in Disease Prevention and Health Promotion.
Stephanie is speaking at
At Epitracker, our mission is to discover novel therapeutics that expand longevity and improve life for both humans and animals. Epitracker is advancing discovery and development of a suite of novel therapeutics aimed to improve global health in the areas of cardiometabolic disease, neurodegenerative disease, and other diseases of aging. Epitracker has demonstrated broad cardiometabolic benefits, mechanism of action, high bioavailablity, and safety of its lead oral therapeutic, ETI-101. Series A financing will be used to advance ETI-101 through FDA IND approval. Epitracker has exclusive licensing rights from the U.S. Navy to five issued U.S. patents and nine pending U.S. and international patents.